Therapeutic effect of repetitive transcranial magnetic stimulation in Parkinson's disease: Analysis of [11C] raclopride PET study
Identifieur interne : 002004 ( Istex/Corpus ); précédent : 002003; suivant : 002005Therapeutic effect of repetitive transcranial magnetic stimulation in Parkinson's disease: Analysis of [11C] raclopride PET study
Auteurs : Ji Youn Kim ; Eun Joo Chung ; Won Yong Lee ; Hee Young Shin ; Gyeong Han Lee ; Yearn-Seong Choe ; Yong Choi ; Byeong Joon KimSource :
- Movement Disorders [ 0885-3185 ] ; 2008-01-30.
English descriptors
- KwdEn :
Abstract
Repetitive transcranial magnetic stimulation (rTMS) has been used as a potential therapeutic tool in Parkinson's disease (PD). However, the therapeutic value and/or the placebo effect of rTMS on PD remain to be elucidated. To investigate the therapeutic value and/or placebo effect of rTMS in PD, we compared the motor section of unified PD rating scale (UPDRS III) and the amount of extracellular dopamine concentration using [11C] raclopride PET before and after two sessions of rTMS in 9 PD patients. During a consecutive 2 days while off‐medication, two series of 15 trains of 5 Hz‐frequency rTMS (intensity, 90% of the resting motor threshold) were applied to the hand area of more severely symptomatic motor cortex (MC). After unilateral rTMS of MC, mean raclopride binding potentials (BPs) were reduced not only in putaminal and caudate areas on the stimulated side (−4.9% and −6.5%, respectively) (P > 0.05) but also in putaminal and caudate areas of nonstimulated hemispheres (−6.6%, P > 0.05 and −12.1%, P = 0.049, respectively). UPDRS III scores were significantly decreased (35.0 ± 14.1 to 32.0 ± 13.4, P = 0.049). A reduction of raclopride BP in nonstimulated ventral striatum by unilateral rTMS supports the placebo response during rTMS. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21787
Links to Exploration step
ISTEX:ED373619261BBD422DBC0FA91FA1B95AD917206BLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic effect of repetitive transcranial magnetic stimulation in Parkinson's disease: Analysis of [11C] raclopride PET study</title><author><name sortKey="Kim, Ji Youn" sort="Kim, Ji Youn" uniqKey="Kim J" first="Ji Youn" last="Kim">Ji Youn Kim</name><affiliation><mods:affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Chung, Eun Joo" sort="Chung, Eun Joo" uniqKey="Chung E" first="Eun Joo" last="Chung">Eun Joo Chung</name><affiliation><mods:affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Lee, Won Yong" sort="Lee, Won Yong" uniqKey="Lee W" first="Won Yong" last="Lee">Won Yong Lee</name><affiliation><mods:affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Shin, Hee Young" sort="Shin, Hee Young" uniqKey="Shin H" first="Hee Young" last="Shin">Hee Young Shin</name><affiliation><mods:affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Lee, Gyeong Han" sort="Lee, Gyeong Han" uniqKey="Lee G" first="Gyeong Han" last="Lee">Gyeong Han Lee</name><affiliation><mods:affiliation>Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Choe, Yearn Eong" sort="Choe, Yearn Eong" uniqKey="Choe Y" first="Yearn-Seong" last="Choe">Yearn-Seong Choe</name><affiliation><mods:affiliation>Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Choi, Yong" sort="Choi, Yong" uniqKey="Choi Y" first="Yong" last="Choi">Yong Choi</name><affiliation><mods:affiliation>Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Kim, Byeong Joon" sort="Kim, Byeong Joon" uniqKey="Kim B" first="Byeong Joon" last="Kim">Byeong Joon Kim</name><affiliation><mods:affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:ED373619261BBD422DBC0FA91FA1B95AD917206B</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.21787</idno><idno type="url">https://api.istex.fr/document/ED373619261BBD422DBC0FA91FA1B95AD917206B/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002004</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Therapeutic effect of repetitive transcranial magnetic stimulation in Parkinson's disease: Analysis of [11C] raclopride PET study</title><author><name sortKey="Kim, Ji Youn" sort="Kim, Ji Youn" uniqKey="Kim J" first="Ji Youn" last="Kim">Ji Youn Kim</name><affiliation><mods:affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Chung, Eun Joo" sort="Chung, Eun Joo" uniqKey="Chung E" first="Eun Joo" last="Chung">Eun Joo Chung</name><affiliation><mods:affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Lee, Won Yong" sort="Lee, Won Yong" uniqKey="Lee W" first="Won Yong" last="Lee">Won Yong Lee</name><affiliation><mods:affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Shin, Hee Young" sort="Shin, Hee Young" uniqKey="Shin H" first="Hee Young" last="Shin">Hee Young Shin</name><affiliation><mods:affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Lee, Gyeong Han" sort="Lee, Gyeong Han" uniqKey="Lee G" first="Gyeong Han" last="Lee">Gyeong Han Lee</name><affiliation><mods:affiliation>Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Choe, Yearn Eong" sort="Choe, Yearn Eong" uniqKey="Choe Y" first="Yearn-Seong" last="Choe">Yearn-Seong Choe</name><affiliation><mods:affiliation>Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Choi, Yong" sort="Choi, Yong" uniqKey="Choi Y" first="Yong" last="Choi">Yong Choi</name><affiliation><mods:affiliation>Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Kim, Byeong Joon" sort="Kim, Byeong Joon" uniqKey="Kim B" first="Byeong Joon" last="Kim">Byeong Joon Kim</name><affiliation><mods:affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-01-30">2008-01-30</date><biblScope unit="vol">23</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="207">207</biblScope><biblScope unit="page" to="211">211</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">ED373619261BBD422DBC0FA91FA1B95AD917206B</idno><idno type="DOI">10.1002/mds.21787</idno><idno type="ArticleID">MDS21787</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>[11C] raclopride PET</term><term>placebo effect</term><term>repetitive transcranial magnetic stimulation</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Repetitive transcranial magnetic stimulation (rTMS) has been used as a potential therapeutic tool in Parkinson's disease (PD). However, the therapeutic value and/or the placebo effect of rTMS on PD remain to be elucidated. To investigate the therapeutic value and/or placebo effect of rTMS in PD, we compared the motor section of unified PD rating scale (UPDRS III) and the amount of extracellular dopamine concentration using [11C] raclopride PET before and after two sessions of rTMS in 9 PD patients. During a consecutive 2 days while off‐medication, two series of 15 trains of 5 Hz‐frequency rTMS (intensity, 90% of the resting motor threshold) were applied to the hand area of more severely symptomatic motor cortex (MC). After unilateral rTMS of MC, mean raclopride binding potentials (BPs) were reduced not only in putaminal and caudate areas on the stimulated side (−4.9% and −6.5%, respectively) (P > 0.05) but also in putaminal and caudate areas of nonstimulated hemispheres (−6.6%, P > 0.05 and −12.1%, P = 0.049, respectively). UPDRS III scores were significantly decreased (35.0 ± 14.1 to 32.0 ± 13.4, P = 0.049). A reduction of raclopride BP in nonstimulated ventral striatum by unilateral rTMS supports the placebo response during rTMS. © 2007 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Ji Youn Kim MD</name><affiliations><json:string>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Eun Joo Chung MD</name><affiliations><json:string>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Won Yong Lee MD, PhD</name><affiliations><json:string>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Hee Young Shin MD</name><affiliations><json:string>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Gyeong Han Lee MD, PhD</name><affiliations><json:string>Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Yearn‐Seong Choe MD, PhD</name><affiliations><json:string>Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Yong Choi PhD</name><affiliations><json:string>Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Byeong Joon Kim MD, PhD</name><affiliations><json:string>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>repetitive transcranial magnetic stimulation</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>[11C] raclopride PET</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>placebo effect</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Repetitive transcranial magnetic stimulation (rTMS) has been used as a potential therapeutic tool in Parkinson's disease (PD). However, the therapeutic value and/or the placebo effect of rTMS on PD remain to be elucidated. To investigate the therapeutic value and/or placebo effect of rTMS in PD, we compared the motor section of unified PD rating scale (UPDRS III) and the amount of extracellular dopamine concentration using [11C] raclopride PET before and after two sessions of rTMS in 9 PD patients. During a consecutive 2 days while off‐medication, two series of 15 trains of 5 Hz‐frequency rTMS (intensity, 90% of the resting motor threshold) were applied to the hand area of more severely symptomatic motor cortex (MC). After unilateral rTMS of MC, mean raclopride binding potentials (BPs) were reduced not only in putaminal and caudate areas on the stimulated side (−4.9% and −6.5%, respectively) (P > 0.05) but also in putaminal and caudate areas of nonstimulated hemispheres (−6.6%, P > 0.05 and −12.1%, P = 0.049, respectively). UPDRS III scores were significantly decreased (35.0 ± 14.1 to 32.0 ± 13.4, P = 0.049). A reduction of raclopride BP in nonstimulated ventral striatum by unilateral rTMS supports the placebo response during rTMS. © 2007 Movement Disorder Society</abstract><qualityIndicators><score>5.231</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1284</abstractCharCount><pdfWordCount>2783</pdfWordCount><pdfCharCount>18197</pdfCharCount><pdfPageCount>5</pdfPageCount><abstractWordCount>204</abstractWordCount></qualityIndicators><title>Therapeutic effect of repetitive transcranial magnetic stimulation in Parkinson's disease: Analysis of [11C] raclopride PET study</title><genre><json:string>Serial article</json:string></genre><host><volume>23</volume><pages><total>5</total><last>211</last><first>207</first></pages><issn><json:string>0885-3185</json:string></issn><issue>2</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2008</publicationDate><copyrightDate>2008</copyrightDate><doi><json:string>10.1002/mds.21787</json:string></doi><id>ED373619261BBD422DBC0FA91FA1B95AD917206B</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/ED373619261BBD422DBC0FA91FA1B95AD917206B/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/ED373619261BBD422DBC0FA91FA1B95AD917206B/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/ED373619261BBD422DBC0FA91FA1B95AD917206B/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Therapeutic effect of repetitive transcranial magnetic stimulation in Parkinson's disease: Analysis of [11C] raclopride PET study</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2008</date></publicationStmt><notesStmt><note>Samsung Medical Center Clinical Research Development Program grant - No. CRS104‐74‐3;</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Therapeutic effect of repetitive transcranial magnetic stimulation in Parkinson's disease: Analysis of [11C] raclopride PET study</title><author><persName><forename type="first">Ji Youn</forename><surname>Kim</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</affiliation></author><author><persName><forename type="first">Eun Joo</forename><surname>Chung</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</affiliation></author><author><persName><forename type="first">Won Yong</forename><surname>Lee</surname><roleName type="degree">MD, PhD</roleName></persName><note type="correspondence"><p>Correspondence: Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50, Irwon‐Dong, Gangnam‐Gu, Seoul 135‐710, Korea</p></note><affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</affiliation></author><author><persName><forename type="first">Hee Young</forename><surname>Shin</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</affiliation></author><author><persName><forename type="first">Gyeong Han</forename><surname>Lee</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</affiliation></author><author><persName><forename type="first">Yearn‐Seong</forename><surname>Choe</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</affiliation></author><author><persName><forename type="first">Yong</forename><surname>Choi</surname><roleName type="degree">PhD</roleName></persName><affiliation>Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</affiliation></author><author><persName><forename type="first">Byeong Joon</forename><surname>Kim</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-01-30"></date><biblScope unit="vol">23</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="207">207</biblScope><biblScope unit="page" to="211">211</biblScope></imprint></monogr><idno type="istex">ED373619261BBD422DBC0FA91FA1B95AD917206B</idno><idno type="DOI">10.1002/mds.21787</idno><idno type="ArticleID">MDS21787</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2008</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Repetitive transcranial magnetic stimulation (rTMS) has been used as a potential therapeutic tool in Parkinson's disease (PD). However, the therapeutic value and/or the placebo effect of rTMS on PD remain to be elucidated. To investigate the therapeutic value and/or placebo effect of rTMS in PD, we compared the motor section of unified PD rating scale (UPDRS III) and the amount of extracellular dopamine concentration using [11C] raclopride PET before and after two sessions of rTMS in 9 PD patients. During a consecutive 2 days while off‐medication, two series of 15 trains of 5 Hz‐frequency rTMS (intensity, 90% of the resting motor threshold) were applied to the hand area of more severely symptomatic motor cortex (MC). After unilateral rTMS of MC, mean raclopride binding potentials (BPs) were reduced not only in putaminal and caudate areas on the stimulated side (−4.9% and −6.5%, respectively) (P > 0.05) but also in putaminal and caudate areas of nonstimulated hemispheres (−6.6%, P > 0.05 and −12.1%, P = 0.049, respectively). UPDRS III scores were significantly decreased (35.0 ± 14.1 to 32.0 ± 13.4, P = 0.049). A reduction of raclopride BP in nonstimulated ventral striatum by unilateral rTMS supports the placebo response during rTMS. © 2007 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>repetitive transcranial magnetic stimulation</term></item><item><term>[11C] raclopride PET</term></item><item><term>Parkinson's disease</term></item><item><term>placebo effect</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2007-07-02">Received</change><change when="2007-09-26">Registration</change><change when="2008-01-30">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/ED373619261BBD422DBC0FA91FA1B95AD917206B/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body" wicri:toSee="Element #text; element #text"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"> <header> <publicationMeta level="product"> <publisherInfo> <publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName> <publisherLoc>Hoboken</publisherLoc> </publisherInfo> <doi registered="yes">10.1002/(ISSN)1531-8257</doi> <issn type="print">0885-3185</issn> <issn type="electronic">1531-8257</issn> <idGroup> <id type="product" value="MDS"></id> </idGroup> <titleGroup> <title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title> <title type="short">Mov. Disord.</title> </titleGroup> </publicationMeta> <publicationMeta level="part" position="20"> <doi origin="wiley" registered="yes">10.1002/mds.v23:2</doi> <numberingGroup> <numbering type="journalVolume" number="23">23</numbering> <numbering type="journalIssue">2</numbering> </numberingGroup> <coverDate startDate="2008-01-30">30 January 2008</coverDate> </publicationMeta> <publicationMeta level="unit" type="article" position="80" status="forIssue"> <doi origin="wiley" registered="yes">10.1002/mds.21787</doi> <idGroup> <id type="unit" value="MDS21787"></id> </idGroup> <countGroup> <count type="pageTotal" number="5"></count> </countGroup> <titleGroup> <title type="articleCategory">Research Article</title> <title type="tocHeading1">Research Articles</title> </titleGroup> <copyright ownership="thirdParty">Copyright © 2007 Movement Disorder Society</copyright> <eventGroup><event type="manuscriptReceived" date="2007-07-02"></event><event type="manuscriptRevised" date="2007-09-10"></event><event type="manuscriptAccepted" date="2007-09-26"></event><event type="firstOnline" date="2007-11-12"></event><event type="publishedOnlineFinalForm" date="2008-01-25"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2007-11-12"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup> <numberingGroup> <numbering type="pageFirst">207</numbering> <numbering type="pageLast">211</numbering> </numberingGroup> <correspondenceTo>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50, Irwon‐Dong, Gangnam‐Gu, Seoul 135‐710, Korea</correspondenceTo> <linkGroup> <link type="toTypesetVersion" href="file:MDS.MDS21787.pdf"></link> </linkGroup> </publicationMeta> <contentMeta> <countGroup> <count type="figureTotal" number="1"></count> <count type="tableTotal" number="2"></count> <count type="referenceTotal" number="25"></count> <count type="wordTotal" number="3281"></count> </countGroup> <titleGroup> <title type="main" xml:lang="en">Therapeutic effect of repetitive transcranial magnetic stimulation in Parkinson's disease: Analysis of [<sup>11</sup>C] raclopride PET study</title> <title type="short" xml:lang="en">Therapeutic Effect of rTMS in Parkinson's Disease</title> </titleGroup> <creators> <creator xml:id="au1" creatorRole="author" affiliationRef="#af1"> <personName> <givenNames>Ji Youn</givenNames> <familyName>Kim</familyName> <degrees>MD</degrees> </personName> </creator> <creator xml:id="au2" creatorRole="author" affiliationRef="#af1"> <personName> <givenNames>Eun Joo</givenNames> <familyName>Chung</familyName> <degrees>MD</degrees> </personName> </creator> <creator xml:id="au3" creatorRole="author" affiliationRef="#af1" corresponding="yes"> <personName> <givenNames>Won Yong</givenNames> <familyName>Lee</familyName> <degrees>MD, PhD</degrees> </personName> <contactDetails> <email>wylee@smc.samsung.co.kr</email> </contactDetails> </creator> <creator xml:id="au4" creatorRole="author" affiliationRef="#af1"> <personName> <givenNames>Hee Young</givenNames> <familyName>Shin</familyName> <degrees>MD</degrees> </personName> </creator> <creator xml:id="au5" creatorRole="author" affiliationRef="#af2"> <personName> <givenNames>Gyeong Han</givenNames> <familyName>Lee</familyName> <degrees>MD, PhD</degrees> </personName> </creator> <creator xml:id="au6" creatorRole="author" affiliationRef="#af2"> <personName> <givenNames>Yearn‐Seong</givenNames> <familyName>Choe</familyName> <degrees>MD, PhD</degrees> </personName> </creator> <creator xml:id="au7" creatorRole="author" affiliationRef="#af2"> <personName> <givenNames>Yong</givenNames> <familyName>Choi</familyName> <degrees>PhD</degrees> </personName> </creator> <creator xml:id="au8" creatorRole="author" affiliationRef="#af1"> <personName> <givenNames>Byeong Joon</givenNames> <familyName>Kim</familyName> <degrees>MD, PhD</degrees> </personName> </creator> </creators> <affiliationGroup> <affiliation xml:id="af1" countryCode="KR" type="organization"> <unparsedAffiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</unparsedAffiliation> </affiliation> <affiliation xml:id="af2" countryCode="KR" type="organization"> <unparsedAffiliation>Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</unparsedAffiliation> </affiliation> </affiliationGroup> <keywordGroup xml:lang="en" type="author"> <keyword xml:id="kwd1">repetitive transcranial magnetic stimulation</keyword> <keyword xml:id="kwd2">[<sup>11</sup>C] raclopride PET</keyword> <keyword xml:id="kwd3">Parkinson's disease</keyword> <keyword xml:id="kwd4">placebo effect</keyword> </keywordGroup> <fundingInfo> <fundingAgency>Samsung Medical Center Clinical Research Development Program grant</fundingAgency> <fundingNumber>CRS104‐74‐3</fundingNumber> </fundingInfo> <abstractGroup> <abstract type="main" xml:lang="en"> <title type="main">Abstract</title> <p>Repetitive transcranial magnetic stimulation (rTMS) has been used as a potential therapeutic tool in Parkinson's disease (PD). However, the therapeutic value and/or the placebo effect of rTMS on PD remain to be elucidated. To investigate the therapeutic value and/or placebo effect of rTMS in PD, we compared the motor section of unified PD rating scale (UPDRS III) and the amount of extracellular dopamine concentration using [<sup>11</sup>C] raclopride PET before and after two sessions of rTMS in 9 PD patients. During a consecutive 2 days while off‐medication, two series of 15 trains of 5 Hz‐frequency rTMS (intensity, 90% of the resting motor threshold) were applied to the hand area of more severely symptomatic motor cortex (MC). After unilateral rTMS of MC, mean raclopride binding potentials (BPs) were reduced not only in putaminal and caudate areas on the stimulated side (−4.9% and −6.5%, respectively) (<i>P</i> > 0.05) but also in putaminal and caudate areas of nonstimulated hemispheres (−6.6%, <i>P</i> > 0.05 and −12.1%, <i>P</i> = 0.049, respectively). UPDRS III scores were significantly decreased (35.0 ± 14.1 to 32.0 ± 13.4, <i>P</i> = 0.049). A reduction of raclopride BP in nonstimulated ventral striatum by unilateral rTMS supports the placebo response during rTMS. © 2007 Movement Disorder Society</p> </abstract> </abstractGroup> </contentMeta> </header> </component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Therapeutic effect of repetitive transcranial magnetic stimulation in Parkinson's disease: Analysis of [11C] raclopride PET study</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Therapeutic Effect of rTMS in Parkinson's Disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Therapeutic effect of repetitive transcranial magnetic stimulation in Parkinson's disease: Analysis of [</title></titleInfo><name type="personal"><namePart type="given">Ji Youn</namePart><namePart type="family">Kim</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Eun Joo</namePart><namePart type="family">Chung</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Won Yong</namePart><namePart type="family">Lee</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</affiliation><description>Correspondence: Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50, Irwon‐Dong, Gangnam‐Gu, Seoul 135‐710, Korea</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hee Young</namePart><namePart type="family">Shin</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gyeong Han</namePart><namePart type="family">Lee</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yearn‐Seong</namePart><namePart type="family">Choe</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yong</namePart><namePart type="family">Choi</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Byeong Joon</namePart><namePart type="family">Kim</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2008-01-30</dateIssued><dateCaptured encoding="w3cdtf">2007-07-02</dateCaptured><dateValid encoding="w3cdtf">2007-09-26</dateValid><copyrightDate encoding="w3cdtf">2008</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">2</extent><extent unit="references">25</extent><extent unit="words">3281</extent></physicalDescription><abstract lang="en">Repetitive transcranial magnetic stimulation (rTMS) has been used as a potential therapeutic tool in Parkinson's disease (PD). However, the therapeutic value and/or the placebo effect of rTMS on PD remain to be elucidated. To investigate the therapeutic value and/or placebo effect of rTMS in PD, we compared the motor section of unified PD rating scale (UPDRS III) and the amount of extracellular dopamine concentration using [11C] raclopride PET before and after two sessions of rTMS in 9 PD patients. During a consecutive 2 days while off‐medication, two series of 15 trains of 5 Hz‐frequency rTMS (intensity, 90% of the resting motor threshold) were applied to the hand area of more severely symptomatic motor cortex (MC). After unilateral rTMS of MC, mean raclopride binding potentials (BPs) were reduced not only in putaminal and caudate areas on the stimulated side (−4.9% and −6.5%, respectively) (P > 0.05) but also in putaminal and caudate areas of nonstimulated hemispheres (−6.6%, P > 0.05 and −12.1%, P = 0.049, respectively). UPDRS III scores were significantly decreased (35.0 ± 14.1 to 32.0 ± 13.4, P = 0.049). A reduction of raclopride BP in nonstimulated ventral striatum by unilateral rTMS supports the placebo response during rTMS. © 2007 Movement Disorder Society</abstract><note type="funding">Samsung Medical Center Clinical Research Development Program grant - No. CRS104‐74‐3; </note><subject lang="en"><genre>Keywords</genre><topic>repetitive transcranial magnetic stimulation</topic><topic>[11C] raclopride PET</topic><topic>Parkinson's disease</topic><topic>placebo effect</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>207</start><end>211</end><total>5</total></extent></part></relatedItem><identifier type="istex">ED373619261BBD422DBC0FA91FA1B95AD917206B</identifier><identifier type="DOI">10.1002/mds.21787</identifier><identifier type="ArticleID">MDS21787</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2007 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002004 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002004 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:ED373619261BBD422DBC0FA91FA1B95AD917206B
|texte= Therapeutic effect of repetitive transcranial magnetic stimulation in Parkinson's disease: Analysis of [11C] raclopride PET study
}}
| This area was generated with Dilib version V0.6.23. |  |